))
Duchenne Muscular Dystrophy: Differentiating Advances in Treatment
Manage episode 414417312 series 3381434
Το περιεχόμενο παρέχεται από το ReachMD. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον ReachMD ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.
CME credits: 0.25
Valid until: 15-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/duchenne-muscular-dystrophy-differentiating-advances-in-treatment/16654/
There are many unmet needs associated with the use of anti-inflammatory glucocorticoids when treating Duchenne muscular dystrophy, or DMD. These include multiple, often debilitating comorbidities that occur with long-term exposure. Join Drs. Hamid, Kuntz, and Monduy as they discuss key clinical trial data for a novel corticosteroid that may be a safer and possibly more effective option for patients with DMD than our current standard of care.=
…
continue reading
Valid until: 15-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/duchenne-muscular-dystrophy-differentiating-advances-in-treatment/16654/
There are many unmet needs associated with the use of anti-inflammatory glucocorticoids when treating Duchenne muscular dystrophy, or DMD. These include multiple, often debilitating comorbidities that occur with long-term exposure. Join Drs. Hamid, Kuntz, and Monduy as they discuss key clinical trial data for a novel corticosteroid that may be a safer and possibly more effective option for patients with DMD than our current standard of care.=
666 επεισόδια
Μοίρασέ το
